A Phase III Double-Blind, Randomized, Placebo Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Intravenous L-citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Subjects Undergoing Surgery for Congenital Heart Defects
Phase of Trial: Phase III
Latest Information Update: 26 Oct 2017
At a glance
- Drugs Citrulline (Primary)
- Indications Acute lung injury
- Focus Registrational; Therapeutic Use
- Sponsors Asklepion Pharmaceuticals
- 13 Oct 2017 Planned End Date changed from 1 Oct 2018 to 1 Apr 2019.
- 13 Oct 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.
- 10 May 2017 Planned End Date changed from 1 Dec 2017 to 1 Oct 2018.